Looks like they are hoping for and targeting an inflection point in 12-18 months time.
Vapendavir may yet promise after re-targeted trials.
Bottom drawer till then.
Biota Pharmaceuticals' CEO Dr. Joseph Patti Interviewed by The Life Sciences Report, page-8
Add to My Watchlist
What is My Watchlist?